Mirabegron | beta-3 Adrenergic agonist
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 10 mg | $50.00 | ||
| 50 mg | $175.00 |
Mirabegron (223673-61-8) is a potent (EC50 = 22.4 nM CHO cells expressing human ß3-ARs) beta-3 adrenergic receptor (ß3-AR) agonist with high selectivity over the beta-1 and beta-2 receptors.1 Clinically useful for the treatment of overactive bladder syndrome. Chronic treatment of human subjects with mirabegron increased brown adipose tissue (BAT) metabolic activity, increased HDL and bile acid levels, and produced substantial improvements in glucose and insulin metabolism.2 Mirabegron inhibited tumor growth in various tumor models including pancreatic ductal adenocarcinoma and hepatocellular carcinoma via altering global metabolism in an uncoupling protein 1 (UCP1; a key protein for non-shivering thermogenesis) dependent manner.3
References/Citations:
- Takasu et al. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function; J. Pharmacol. Exp. Ther. 321 642
- O’Mara et al. (2020) Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity; J. Clin. Invest. 130 2209
- Sun et al. (2023) Mirabegron displays anticancer effects by globally browning adipose tissues; Nat. Commun. 14 7610
C21H24N4O2S
>98% by HPLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Mirabegron (223673-61-8) is a potent (EC50 = 22.4 nM CHO cells expressing human ß3-ARs) beta-3 adrenergic receptor (ß3-AR) agonist with high selectivity over the beta-1 and beta-2 receptors.1 Clinically useful for the treatment of overactive bladder syndrome. Chronic treatment of human subjects with mirabegron increased brown adipose tissue (BAT) metabolic activity, increased HDL and bile acid levels, and produced substantial improvements in glucose and insulin metabolism.2 Mirabegron inhibited tumor growth in various tumor models including pancreatic ductal adenocarcinoma and hepatocellular carcinoma via altering global metabolism in an uncoupling protein 1 (UCP1; a key protein for non-shivering thermogenesis) dependent manner.3
References/Citations:
- Takasu et al. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function; J. Pharmacol. Exp. Ther. 321 642
- O’Mara et al. (2020) Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity; J. Clin. Invest. 130 2209
- Sun et al. (2023) Mirabegron displays anticancer effects by globally browning adipose tissues; Nat. Commun. 14 7610
Related products
-
Imiquimod | TLR7 Agonist
From $30.00CAS:99011-02-6Catalog Number:10-4230Alternate Name:R837Activity:TLR7 agonistChemical Name:1-(2-Methylpropyl)imidazo[4,5-c]quinolin-4-amineMolecular Weight:240.30Molecular Formula:C14H16N4Solubility:Soluble in DMSO (2 mg/ml with warming)Physical Properties:White solidPurity:>98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
Levetiracetam | Anticonvulsant
From $45.00CAS:102767-28-2Catalog Number:10-2040Activity:AnticonvulsantChemical Name:2(S)-(2-Oxopyrrolidin-1-yl)butyramideMolecular Weight:170.21Molecular Formula:C29H14N2O2Solubility:Soluble in DMSO (up to at least 25 mg/ml).Physical Properties:White solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.Shipping Code:RT -
Rucaparib phosphate | PARP1 inhibitor
From $70.00CAS:459868-92-9Catalog Number:10-3321Activity:PARP1 inhibitorChemical Name:8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-oneAlternate Name:AG-14699; PF01367338Molecular Weight:421.36Molecular Formula:C19H18FN3O • H3PO4Solubility:Soluble in DMSO (up to 25 mg/ml).Physical Properties:Yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
